Table 1.

Oral antidiabetes drug use in seven case subjects with lactic acidosis

Case no.	Age (years)/sex	Use of oral antidiabetes drugs	Approximate duration of metformin use prior to diagnosis (months)	Time between last metformin prescription and diagnosis (days)	Relevant comorbidities and outcome (died or survived)
1	83/female	Metformin, glibenclamide	57	21	Acute renal failure, acute heart failure (hypertensive heart disease) (died)
2	63/female	Metformin, gliclazide	11	13	Acute seizure, stable hypertensive heart disease, nonexacerbated chronic obstructive pulmonary disease (survived)
3	70/female	Gliclazide	—	—	Urosepsis (survived)
4	74/male	Metformin, gliclazide	11	106*	Stable hypertensive heart disease, nonexacerbated chronic obstructive pulmonary disease (survived)
5	82/female	Metformin	29	52	Acute gastroenteritis with hypovolemia (died)
6	42/female	Metformin, pioglitazone	82	7	Stable hypertensive heart disease, liver cirrhosis (survived)
7	70/male	Metformin, gliclazide	32	36	Acute heart failure (hypertensive heart disease) (survived)

^*Patient no. 4 was classified as a “past metformin user” because the tablet supply of the last metformin prescription prior to the index date was likely to not last up to or beyond the index date (for details, see text).